Acute Hepatotoxicity of Intravenous Amiodarone: Case Report and Review of the Literature

American Journal of Therapeutics

Volumn 23, Issue 1, 2016, Pages e260-e263

  Chen, Chia Chi ^a   Wu, Chien Chih ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

adverse drug reaction; amiodarone; hepatotoxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; CLOPIDOGREL; ISOSORBIDE MONONITRATE; LIDOCAINE; LIVER ENZYME; MEXILETINE; POLYSORBATE 80; ANTIARRHYTHMIC AGENT;

ACUTE HEPATOTOXICITY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATRIAL FIBRILLATION; BLURRED VISION; CALCIFICATION; CASE REPORT; CHEST TIGHTNESS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG WITHDRAWAL; HEART CATHETERIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MALE; MIDDLE AGED; PRIORITY JOURNAL; SLURRED SPEECH; WEAKNESS; ACUTE DISEASE; CHEMICAL AND DRUG INDUCED LIVER INJURY; INTRAVENOUS DRUG ADMINISTRATION; TACHYCARDIA, VENTRICULAR;

ACUTE DISEASE; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; TACHYCARDIA, VENTRICULAR;

EID: 84955751997     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000149     Document Type: Article

References (27)

1. Parfitt K, Martindale W. Martindale: The Complete Drug Reference. 38th ed. London, United Kingdom: Pharmaceutical Press; 2014.
2. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250-1259.
3. Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000;160:1741-1748.
4. McEvoy GK. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2014.
5. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex, [cited 2014.06.01]. Available from: http://www.micromedexsolutions.com.
6. Apotex Inc. Product Information: Amiodarone Hydrochloride Injection. Toronto, Canada: Apotex Inc; 2006.
7. Huang X, Yang Y, Zhu J, et al. Clinical applications and acute hepatotoxicity of intravenous amiodarone. J Int Med Res. 2009;37:1928-1936.
8. Ratz Bravo AE, Drewe J, Schlienger RG, et al. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med. 2005;33:128-134; discussion 245-246.
9. Stravitz RT. Critical management decisions in patients with acute liver failure. Chest. 2008;134:1092-1102.
10. Gregory SA, Webster JB, Chapman GD. Acute hepatitis induced by parenteral amiodarone. Am J Med. 2002;113: 254-255.
11. Maker AV, Orgill DP. Rapid acute amiodarone-induced hepatotoxicity in a burn patient. J Burn Care Rehabil. 2005; 26:341-343.
12. Rao U, Agarwal A. Amiodarone-induced acute hepatotoxicity. Eur J Clin Pharmacol. 2012;68:449-450.
13. Kicker JS, Haizlip JA, Buck ML. Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant. J Pediatr Pharmacol Ther. 2012;17:189-195.
14. Nasser M, Larsen TR, Waanbah B, et al. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. Drug Healthc Patient Saf. 2013;5:191-198.
15. Zahno A, Brecht K, Morand R, et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol. 2011;81:432-441.
16. Lahbabi M, Aqodad N, Ibrahimi A, et al. Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy. World J Hepatol. 2012;4:196-198.
17. Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? Gut. 1993;34:565-566.
18. Balistreri WF, Farrell MK, Bove KE. Lessons from the E-Ferol tragedy. Pediatrics. 1986;78:503-506.
19. Arrowsmith JB, Faich GA, Tomita DK, et al. Morbidity and mortality among low birth weight infants exposed to an intravenous vitamin E product, E-Ferol. Pediatrics. 1989;83:244-249.
20. Mystery of the E-Ferol syndrome. Nutr Rev. 1987;45:76-77.
21. Conyers RA, Bais R, Rofe AM. Oxalosis and the E-Ferol toxicity syndrome. JAMA. 1986;256:2677-2678.
22. Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77:593-597.
23. Brown RE, Alade SL, Krouse MA. Polysorbates and renal oxalate crystals in the E-Ferol syndrome. JAMA. 1986; 255:2445.
24. Lorch V, Murphy D, Hoersten LR, et al. Unusual syndrome among premature infants: association with a new intravenous vitamin E product. Pediatrics. 1985;75:598-602.
25. Bove KE, Kosmetatos N, Wedig KE, et al. Vasculopathic hepatotoxicity associated with E-Ferol syndrome in lowbirth-weight infants. JAMA. 1985;254:2422-2430.
26. Waldhauser KM, Torok M, Ha HR, et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther. 2006;319: 1413-1423.
27. James PR, Hardman SM. Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy. Heart. 1997;77:583-584.